is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. Harvoni is a fixed-dose combination of Ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and Sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor.

Manufactured by: Gilead Sciences.Inc.

Active Ingredient(s): Ledipasvir; Sofosbuvir

Dosage Form: Tablet, oral

Strength: 90 mg; 400 mg

FDA approved: October 10, 2014
More information about Harvoni:

http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf